Adverse effects of androgen-deprivation therapy in prostate cancer and their management

被引：117
作者：
Rhee, Handoo [1 ,3 ]
Gunter, Jennifer H. [3 ]
Heathcote, Peter [1 ,3 ]
Ho, Ken [2 ]
Stricker, Phillip [4 ,5 ]
Corcoran, Niall M. [6 ]
Nelson, Colleen C. [3 ]
机构：
[1] Princess Alexandra Hosp, Dept Urol, Brisbane, Qld, Australia
[2] Princess Alexandra Hosp, Ctr Hlth Res, Brisbane, Qld, Australia
[3] Queensland Univ Technol, Princess Alexandra Hosp, Australian Prostate Canc Res Ctr, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia
[4] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia
[5] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[6] Epworth Healthcare, Epworth Prostate Ctr, Melbourne, Vic, Australia
来源：
BJU INTERNATIONAL | 2015年 / 115卷
关键词：
androgen-deprivation therapy; prostate cancer; adverse effect; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; METASTASIS-FREE SURVIVAL; BONE LOSS; CARDIOVASCULAR RISK; FRACTURE RISK; MEN; INTERMITTENT; OSTEOPOROSIS; DENOSUMAB;
D O I：
10.1111/bju.12964
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Objective To provide an up-to-date summary of current literature on the management of adverse effects of androgen-deprivation therapy (ADT). Patients and Methods All relevant medical literature on men with prostate cancer treated with ADT from 2005 to 2014, and older relevant papers, were reviewed. Recent health advisory statements from the Australian government, societies and advocacy groups have been incorporated to the document. Results There are numerous adverse effects of ADT that require pro-active prevention and treatment. Ranging from cardiovascular disease, diabetes and osteoporosis, to depression, cognitive decline and sexual dysfunction, the range of adverse effects is wide. Baseline assessment, monitoring, prevention and consultation from a multidisciplinary team are important in minimising the harm from ADT. Conclusions This review provides a series of practical recommendations to assist with managing the adverse effects of ADT.
引用
收藏
页码：3 / 13
页数：11
相关论文
共 64 条
[41]   Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer [J].
Pagliarulo, Vincenzo ;
Bracarda, Sergio ;
Eisenberger, Mario A. ;
Mottet, Nicolas ;
Schroeder, Fritz H. ;
Sternberg, Cora N. ;
Studer, Urs E. .
EUROPEAN UROLOGY, 2012, 61 (01) :11-25
[42]   Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes study [J].
Potosky, AL ;
Knopf, K ;
Clegg, LX ;
Albertsen, PC ;
Stanford, JL ;
Hamilton, AS ;
Gilliland, FD ;
Eley, JW ;
Stephenson, RA ;
Hoffman, RM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (17) :3750-3757
[43]   Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302) [J].
Rathkopf, Dana E. ;
Smith, Matthew R. ;
de Bono, Johann S. ;
Logothetis, Christopher J. ;
Shore, Neal D. ;
de Souza, Paul ;
Fizazi, Karim ;
Mulders, Peter F. A. ;
Mainwaring, Paul ;
Hainsworth, John D. ;
Beer, Tomasz M. ;
North, Scott ;
Fradet, Yves ;
Van Poppel, Hendrik ;
Carles, Joan ;
Flaig, Thomas W. ;
Efstathiou, Eleni ;
Yu, Evan Y. ;
Higano, Celestia S. ;
Taplin, Mary-Ellen ;
Griffin, Thomas W. ;
Todd, Mary B. ;
Yu, Margaret K. ;
Park, Youn C. ;
Kheoh, Thian ;
Small, Eric J. ;
Scher, Howard I. ;
Molina, Arturo ;
Ryan, Charles J. ;
Saad, Fred .
EUROPEAN UROLOGY, 2014, 66 (05) :815-825
[44]   Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis [J].
Serpa Neto, A. ;
Tobias-Machado, M. ;
Esteves, M. A. P. ;
Senra, M. D. ;
Wroclawski, M. L. ;
Fonseca, F. L. A. ;
dos Reis, R. B. ;
Pompeo, A. C. L. ;
Giglio, A. D. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (01) :36-44
[45]   Avoiding obsolescence in advanced prostate cancer management: a guide for urologists [J].
Shore, Neal D. ;
Karsh, Lawrence ;
Gomella, Leonard G. ;
Keane, Thomas E. ;
Concepcion, Raoul S. ;
Crawford, E. David .
BJU INTERNATIONAL, 2015, 115 (02) :188-197
[46]   Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time [J].
Smith, Matthew R. ;
Saad, Fred ;
Oudard, Stephane ;
Shore, Neal ;
Fizazi, Karim ;
Sieber, Paul ;
Tombal, Bertrand ;
Damiao, Ronaldo ;
Marx, Gavin ;
Miller, Kurt ;
Van Veldhuizen, Peter ;
Morote, Juan ;
Ye, Zhishen ;
Dansey, Roger ;
Goessl, Carsten .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (30) :3800-+
[47]   Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial [J].
Smith, Matthew R. ;
Saad, Fred ;
Coleman, Robert ;
Shore, Neal ;
Fizazi, Karim ;
Tombal, Bertrand ;
Miller, Kurt ;
Sieber, Paul ;
Karsh, Lawrence ;
Damiao, Ronaldo ;
Tammela, Teuvo L. ;
Egerdie, Blair ;
Van Poppel, Hendrik ;
Chin, Joseph ;
Morote, Juan ;
Gomez-Veiga, Francisco ;
Borkowski, Tomasz ;
Ye, Zhishen ;
Kupic, Amy ;
Dansey, Roger ;
Goessl, Carsten .
LANCET, 2012, 379 (9810) :39-46
[48]   Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer [J].
Smith, Matthew R. ;
Egerdie, Blair ;
Toriz, Narciso Hernandez ;
Feldman, Robert ;
Tammela, Teuvo L. J. ;
Saad, Fred ;
Heracek, Jiri ;
Szwedowski, Maciej ;
Ke, Chunlei ;
Kupic, Amy ;
Leder, Benjamin Z. ;
Goessl, Carsten .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (08) :745-755
[49]   Insulin sensitivity during combined androgen blockade for prostate cancer [J].
Smith, MR ;
Lee, H ;
Nathan, DM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (04) :1305-1308
[50]   Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer [J].
Smith, MR ;
Eastham, J ;
Gleason, DM ;
Shasha, D ;
Tchekmedyian, S ;
Zinner, N .
JOURNAL OF UROLOGY, 2003, 169 (06) :2008-2012
1234567